‘Rebuild clinical trials business’

Hyderabad: In the wake of the Covid-19 pandemic, where every country is joining the race to develop a vaccine, Biocon Limited executive chairperson Kiran Mazumdar Shaw said it is important to rebuild the country’s clinical trials business on the foundation of ethics and research temper.
“Clinical trial is a very important area for innovation as it is about clinical research.And for doing clinical research, we have all the ingredients that are required – we have the human resource for conducting clinical trials, patient population with diverse disease condition, hospital infrastructure and IT capabilities. In the case of Covid-19, over 200 clinical trials are going on globally and everybody is scrambling for the right patient but unfortunately in India, we look at clinical trials as if it is ‘rent-a-patient’,” she said.
While participating in Ficci FLO’s webinar ‘Towards a New Health’ here on Friday, the Biocon founder pointed out the focus must be on building credibility of the clinal trials process in the country as it is a huge job creator and spurs innovation.
Meanwhile, advocating for better integration of technology into the healthcare sector, Sangita Reddy, president, Ficci, and joint MD of Apollo Hospitals said, “ It deeply impacts the three significant tenets of healthcare -- accessible healthcare for everyone, quality healthcare, and affordable healthcare. If we merge and use technology in the right manner, we can make a significant difference.”